Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025

Reuters

2025/10/15

<a href="https://laohu8.com/S/TEM">Tempus AI</a> Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025

Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575578237"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575578237\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575578237?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575578237","market":"fut","top_or_hot":-1,"title":"Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-15 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL6m0dcP:1","article_id":"2575578237","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575578237","pubTimestamp":1760531434,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology  Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer  sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI","BK4613":"AI应用软件","BK4121":"生命科学工具和服务","BK4611":"AI医疗","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"translate_title":"Tempus AI宣布将在2025年ESMO大会上展示精准癌症治疗的新临床试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":0.9},"content_text":"Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025\n    \n\n        Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}